These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6145276)

  • 1. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests.
    Nortier JW; Croughs RJ; Thijssen JH; Schwarz F
    Clin Endocrinol (Oxf); 1984 May; 20(5):565-71. PubMed ID: 6744634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term bromocriptine therapy and predictive tests in acromegaly.
    Karashima T; Kato K; Nawata H; Ikuyama S; Ibayashi H; Okamura K; Shiroozu A; Nakashima T; Fujishima M
    Endocrinol Jpn; 1986 Apr; 33(2):163-7. PubMed ID: 3093202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone responses to the releasing hormones GHRH and GnRH and the inhibitors somatostatin and bromocriptine in TRH-responsive and non-responsive acromegalics.
    Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):53-8. PubMed ID: 2889308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acromegaly with bromocriptine.
    Wang C; Chan V; Yeung RT
    Aust N Z J Med; 1979 Jun; 9(3):225-32. PubMed ID: 288387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
    Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No acute effect of pimozide on the plasma GH levels in acromegaly.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
    Fredstorp L; Kutz K; Werner S
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
    Campino C; Szecowka J; Lopez JM; Seron-Ferre M
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
    Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
    Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
    Schwinn G; Dirks H; McIntosh C; Köbberling J
    Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T; Nowak S
    Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
    Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
    Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F
    Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.
    Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S
    J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.